Lilly, Gilead, Amgen started at outperform by Bernstein
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
Jefferies Remains a Buy on Amgen (AMGN)
Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...
Buy Rating Affirmed: Gilead’s Breakthrough HIV Prevention and Promising Long-Acting Treatments
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
PharmiWeb19m
Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR
With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...
Cancer Gene Therapy Market Projected To Reach $11.4 Billion By 2030 At A 23.3% CAGR: Gilead Sciences, Genulex, Amgen Inc
PORTLAND, CA, UNITED STATES, October 7, 2024 /EINPresswire / -- According to the report, the global cancer gene therapy <a target=_blank href=ht ...
7 Best Pharmaceutical Stocks to Buy for Income
The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...
Bernstein starts healthcare sector, rates three stocks as Buy
Bernstein said Thursday it has started research coverage of US biopharma stocks, voicing a positive outlook for the sector.
Le Lézard6d
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with ...